You just read:

Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks

News provided by

Array BioPharma

04 Jun, 2016, 09:00 ET